Strategies for the comprehensive treatment of gastric cancer ovarian metastasis.

IF 2.6 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-06-24 DOI:10.5306/wjco.v16.i6.106589

Si-Jia Wu, Chu-Ying Wu, Kai Ye

{"title":"Strategies for the comprehensive treatment of gastric cancer ovarian metastasis.","authors":"Si-Jia Wu, Chu-Ying Wu, Kai Ye","doi":"10.5306/wjco.v16.i6.106589","DOIUrl":null,"url":null,"abstract":"<p><p>The incidence of gastric cancer is currently increasing, with gastrectomy and D2 Lymphadenectomy being the primary treatments for resectable gastric cancer. For advanced or unresectable metastatic gastric cancer, systemic treatment options include chemotherapy, targeted therapy, or immunotherapy. Krukenberg tumours are types of metastatic tumours in the ovaries that exclusively occur in female patients and that originate from the stomach. Previously deemed an incurable stage of advanced disease, the prognosis of patients with ovarian metastases from gastric cancer depends on multiple factors, including tumour biology and treatment response. With the development of comprehensive cancer treatment options, the combination of surgery and chemotherapy has gradually become the primary treatment for patients with ovarian metastasis from gastric cancer. Individualised comprehensive treatment regimens are crucial for improving patient outcomes. This review summarises the comprehensive treatment strategies for ovarian metastasis from gastric cancer.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"106589"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198853/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i6.106589","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The incidence of gastric cancer is currently increasing, with gastrectomy and D2 Lymphadenectomy being the primary treatments for resectable gastric cancer. For advanced or unresectable metastatic gastric cancer, systemic treatment options include chemotherapy, targeted therapy, or immunotherapy. Krukenberg tumours are types of metastatic tumours in the ovaries that exclusively occur in female patients and that originate from the stomach. Previously deemed an incurable stage of advanced disease, the prognosis of patients with ovarian metastases from gastric cancer depends on multiple factors, including tumour biology and treatment response. With the development of comprehensive cancer treatment options, the combination of surgery and chemotherapy has gradually become the primary treatment for patients with ovarian metastasis from gastric cancer. Individualised comprehensive treatment regimens are crucial for improving patient outcomes. This review summarises the comprehensive treatment strategies for ovarian metastasis from gastric cancer.

查看原文本刊更多论文

胃癌卵巢转移的综合治疗策略。

目前胃癌的发病率呈上升趋势，胃切除术和D2淋巴结切除术是可切除胃癌的主要治疗方法。对于晚期或不可切除的转移性胃癌，全身治疗方案包括化疗、靶向治疗或免疫治疗。Krukenberg肿瘤是一种卵巢转移性肿瘤，只发生在女性患者身上，起源于胃。胃癌卵巢转移患者的预后取决于多种因素，包括肿瘤生物学和治疗反应，此前被认为是晚期疾病的不可治愈阶段。随着肿瘤综合治疗方案的发展，手术与化疗相结合逐渐成为胃癌卵巢转移患者的主要治疗方法。个体化综合治疗方案对改善患者预后至关重要。本文就胃癌卵巢转移的综合治疗策略作一综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.